Litigation Details for Impax Laboratories Inc. v. Lannett Holdings Inc. (D. Del. 2014)
✉ Email this page to a colleague
Impax Laboratories Inc. v. Lannett Holdings Inc. (D. Del. 2014)
| Docket | ⤷ Try a Trial | Date Filed | 2014-07-25 |
| Court | District Court, D. Delaware | Date Terminated | 2017-04-17 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | ASTRAZENECA AB; LANNETT COMPANY INC. | ||
| Patents | 6,750,237; 7,220,767; 9,289,432 | ||
| Attorneys | Danielle A. Duszczyszyn; Stefan M. Miller | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Impax Laboratories Inc. v. Lannett Holdings Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Impax Laboratories Inc. v. Lannett Holdings Inc. (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-10-11 | 140 | opinion PX‐221 3/22/2016 Patent: U.S. Patent No. 9,289,432 B2, Issued to Gizurarson …The ’237 patent is subject to a patent term extension of 0 days. B. The ’767 Patent …disclaimer over the ’237 patent. 22. The ’767 patent is subject to a patent term extension of… ’237 patent and ’767 patent were at the time of the invention of the claims of those patents. … ’237 patent and ’767 patent were at the time of the invention of the claims of those patents. | External link to document | |
| 2017-03-29 | 169 | infringement of U.S. Patent Nos. 6, 750,237 and 7,220, 767 ("the Dearn patents"). The…suit, (2) the Dearn patents are invalid as anticipated, and (3) the Dearn patents are invalid as obvious… the patent context, standing usually requires the plaintiff to have legal title to the patent. Abraxis…November 28, 2000. The patents claim priority from a 1999 United Kingdom patent application, No. 9928578.5… UK patent application. (PX 239). Plaintiffs contend this assignment applies to the Dearn patents. (D.I | External link to document | |
| 2017-04-19 | 175 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,750,237 B1; 7,220,767 B2. (…2014 17 April 2017 1:14-cv-00984 830 Patent None District Court, D. Delaware | External link to document | |
| 2014-07-25 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,750,237 B2; 7,220,767 B2. (…2014 17 April 2017 1:14-cv-00984 830 Patent None District Court, D. Delaware | External link to document | |
| 2015-11-30 | 60 | of several terms in U.S. Patent Nos. 6;750,237 ("the '237 patent") and 7,220,767 ("…construction for disputed terms in U.S. Patent Nos. 6,750,237 and 7,220,767. Within five days the parties…quot;It is a bedrock principle of patent law that the claims of a patent define the invention fo which …that the patents claim intranasal formulations. More importantly, review of the patents as a whole… 6 patent, 1:31-36, 2:7-9). Third, Examples 1-8 of the patents are directed to intranasal | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
